ArticleFrontiers in pharmacology2020
Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06665919 (Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI: Meta-analysis.Clinical and translational science · 2025Pooled it
- Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.BMC cardiovascular disorders · 2022Pooled it
- Effectiveness of CYP2C19 Genotype-Guided Antiplatelet Therapy Following Neurovascular Endovascular Procedures: A Prospective Non-Randomized Controlled Study.Therapeutics and clinical risk management · 2026Article
- Research progress on de-escalation strategies of dual antiplatelet therapy after acute coronary syndrome.Frontiers in medicine · 2026Article
- Risk factors and predictive model for mortality in acute myocardial infarction with ventricular septal rupture at high altitudes.World journal of cardiology · 2025Article
- Implementation of genetic testing for heritable cardiac conditions: A scoping review.Genetics in medicine open · 2025Review
- Population-specific genetic differences of acute coronary syndrome in Han and Uyghur Chinese.Frontiers in pharmacology · 2025Article
- Genetic and clinical determinants of MACE and haemorrhage in antiplatelet therapy: insights from pharmacogenomic analysis.Frontiers in cardiovascular medicine · 2025Article
- Genetic Determinants of Response to P2YInterventional cardiology clinics · 2024Review
- Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies.Clinical and translational science · 2024Article
- From genes to drugs:Frontiers in pharmacology · 2024Review
- Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients.Global heart · 2023Article
- A HANC Risk Stratification Score for Antiplatelet Therapy Optimization with Low-Dose Prasugrel in Taiwanese Acute Coronary Syndrome Patients from the Switch Study.Acta Cardiologica Sinica · 2022Article
- Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.Human genomics · 2022Article
- Evaluation of race and ethnicity disparities in outcome studies ofFrontiers in cardiovascular medicine · 2022Review
- CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study.Frontiers in cardiovascular medicine · 2022Article
- Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.